Patient characteristics according to Bcl-6 expression and treatment
. | . | Study population . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Total* . | . | Bcl-6+ . | . | . | Bcl-6- . | . | . | |||||||
| Patient characteristic . | Intergroup trial . | CHOP . | R-CHOP . | CHOP . | R-CHOP . | P . | CHOP . | R-CHOP . | P . | |||||||
| No. of patients | 544 | 92 | 107 | 68 | 86 | NA | 24 | 21 | NA | |||||||
| No. men (%) | 272 (50) | 43 (47) | 56 (52) | 32 (47) | 49 (57) | .3 | 11 (46) | 7 (33) | .5 | |||||||
| Median age, y (range) | 70 (60-92) | 71 (61-87) | 71 (60-85) | 71 (61-87) | 70 (60-85) | .9 | 68 (61-82) | 71 (60-80) | .5 | |||||||
| Elevated LDH level, no. (%) | 321 (59) | 59 (64) | 65 (61) | 42 (62) | 50 (58) | .7 | 17 (71) | 15 (71) | .9 | |||||||
| Stage III-IV, no. (%) | 403 (74) | 74 (80) | 85 (79) | 54 (79) | 70 (81) | .8 | 20 (83) | 15 (71) | .5 | |||||||
| ECOG PS greater than 1, no. (%) | 78 (14) | 11 (12) | 18 (17) | 9 (13) | 14 (16) | .7 | 2 (8) | 4 (19) | .4 | |||||||
| More than 1 extranodal site, no. (%) | 162 (30) | 27 (29) | 32 (30) | 19 (28) | 29 (34) | .5 | 8 (33) | 3 (14) | .2 | |||||||
| BM involvement, no. (%) | 111 (20) | 18 (20) | 19 (18) | 12 (18) | 15 (17) | .9 | 6 (25) | 4 (19) | .7 | |||||||
| HI/high IPI, no. (%) | 327 (60) | 59 (64) | 67 (63) | 42 (62) | 55 (64) | .9 | 17 (71) | 12 (57) | .4 | |||||||
| HI/high age-adjusted IPI, no. (%) | 280 (51) | 51 (55) | 59 (55) | 37 (54) | 47 (55) | .9 | 14 (58) | 12 (57) | .9 | |||||||
. | . | Study population . | . | . | . | . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Total* . | . | Bcl-6+ . | . | . | Bcl-6- . | . | . | |||||||
| Patient characteristic . | Intergroup trial . | CHOP . | R-CHOP . | CHOP . | R-CHOP . | P . | CHOP . | R-CHOP . | P . | |||||||
| No. of patients | 544 | 92 | 107 | 68 | 86 | NA | 24 | 21 | NA | |||||||
| No. men (%) | 272 (50) | 43 (47) | 56 (52) | 32 (47) | 49 (57) | .3 | 11 (46) | 7 (33) | .5 | |||||||
| Median age, y (range) | 70 (60-92) | 71 (61-87) | 71 (60-85) | 71 (61-87) | 70 (60-85) | .9 | 68 (61-82) | 71 (60-80) | .5 | |||||||
| Elevated LDH level, no. (%) | 321 (59) | 59 (64) | 65 (61) | 42 (62) | 50 (58) | .7 | 17 (71) | 15 (71) | .9 | |||||||
| Stage III-IV, no. (%) | 403 (74) | 74 (80) | 85 (79) | 54 (79) | 70 (81) | .8 | 20 (83) | 15 (71) | .5 | |||||||
| ECOG PS greater than 1, no. (%) | 78 (14) | 11 (12) | 18 (17) | 9 (13) | 14 (16) | .7 | 2 (8) | 4 (19) | .4 | |||||||
| More than 1 extranodal site, no. (%) | 162 (30) | 27 (29) | 32 (30) | 19 (28) | 29 (34) | .5 | 8 (33) | 3 (14) | .2 | |||||||
| BM involvement, no. (%) | 111 (20) | 18 (20) | 19 (18) | 12 (18) | 15 (17) | .9 | 6 (25) | 4 (19) | .7 | |||||||
| HI/high IPI, no. (%) | 327 (60) | 59 (64) | 67 (63) | 42 (62) | 55 (64) | .9 | 17 (71) | 12 (57) | .4 | |||||||
| HI/high age-adjusted IPI, no. (%) | 280 (51) | 51 (55) | 59 (55) | 37 (54) | 47 (55) | .9 | 14 (58) | 12 (57) | .9 | |||||||
NA indicates not applicable.
P > .4 for all comparisons, CHOP versus R-CHOP.